Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel

Thrombosis Research

Volumn 124, Issue 5, 2009, Pages 546-553

  Lordkipanidzé, Marie ^a,b   Pharand, Chantal ^a,b   Palisaitis, Donald A ^a,b   Schampaert, Erick ^a,b   Diodati, Jean G ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Clopidogrel; Platelet aggregation; Platelet function testing; Response variability

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGED; ANALYTIC METHOD; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; HUMAN; INTROSPECTION; LIGHT; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PARAMETER; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 70349857877     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.04.003     Document Type: Article

References (35)

1. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-286
2. Bassand J.P., Hamm C.W., Ardissino D., Boersma E., Budaj A., Fernandez-Aviles F., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28 (2007) 1598-1660
3. Angiolillo D.J., Bhatt D.L., Gurbel P.A., and Jennings L.K. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 103 (2009) 40A-51A
4. Murugappan S., Shankar H., and Kunapuli S.P. Platelet receptors for adenine nucleotides and thromboxane A2. Semin Thromb Hemost 30 (2004) 411-418
5. Jarvis G.E., Humphries R.G., Robertson M.J., and Leff P. ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors. Br J Pharmacol 129 (2000) 275-282
6. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 108 (2005) 180-192
7. Labarthe B., Theroux P., Angioi M., and Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 46 (2005) 638-645
8. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., and Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1822-1834
9. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
10. Schafer A., Weinberger S., Flierl U., Eigenthaler M., Stork S., Walter U., et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 100 (2008) 618-625
11. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., and Kopp C.W. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 101 (2009) 333-339
12. Bal Dit Sollier C., Berge N., Boval B., Hovsepian L., and Drouet L. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 101 (2009) 116-122
13. Matetzky S., Fefer P., Shenkman B., Varon D., Savion N., and Hod H. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol 102 (2008) 524-529
14. Gurbel P.A., Bliden K.P., Etherington A., and Tantry U.S. Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 121 (2007) 107-115
15. van Werkum J.W., Kleibeuker M., Mieremet N., ten Berg J.M., and Hackeng C.M. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?. J Thromb Haemost 5 (2007) 884-886
16. Marcucci R., Paniccia R., Antonucci E., Poli S., Gori A.M., Valente S., et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 98 (2007) 844-851
17. Chatburn R.L. Evaluation of instrument error and method agreement. Aana J 64 (1996) 261-268
18. Bland J.M., and Altman D.G. Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol 22 (2003) 85-93
19. Lordkipanidzé M., Pharand C., Nguyen T.A., Schampaert E., Palisaitis D.A., and Diodati J.G. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 29 (2008) 2877-2885
20. Pharand C., Nguyen T.A., Lordkipanidzé M., Palisaitis D.A., Turgeon J., Schampaert E., et al. Prolonged prophylactic administration of high-dose clopidogrel before elective percutaneous coronary intervention is more effective than the standard 300 mg bolus in inhibiting platelet aggregation (abstract). Arterioscler Thromb Vasc Biol 27 (2007) e110
21. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
22. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
23. Breddin H.K. Can platelet aggregometry be standardized?. Platelets 16 (2005) 151-158
24. Linnemann B., Schwonberg J., Mani H., Prochnow S., and Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 6 (2008) 677-683
25. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
26. Baurand A., Eckly A., Bari N., Leon C., Hechler B., Cazenave J.P., et al. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost 84 (2000) 484-491
27. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
28. FitzGerald G.A. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 68 (1991) 11B-15B
29. Samara W.M., Bliden K.P., Tantry U.S., and Gurbel P.A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 115 (2005) 89-94
30. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
31. Cuisset T., Frere C., Quilici J., Barbou F., Morange P.E., Hovasse T., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 (2006) 542-549
32. Campo G., Valgimigli M., Gemmati D., Percoco G., Tognazzo S., Cicchitelli G., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 48 (2006) 2178-2185
33. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24 (2004) 1980-1987
34. Michelson A.D. Platelet function testing in cardiovascular diseases. Circulation 110 (2004) e489-e493
35. Michelson A.D., Cattaneo M., Eikelboom J.W., Gurbel P., Kottke-Marchant K., Kunicki T.J., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311